Dark

Check out our API

XLRN
Acceleron Pharma Inc.
stock NASDAQ

Inactive

Nov 19, 2021

178.75USD-0.518%(-0.93)7,884,284

Pre-market

0.00USD-100.000%(-179.68)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 17, 2021

02:26PM EST Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer Business Wire

06:46AM EST Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period And Extension Of Tender Offer To Acquire Acceleron Pharma Inc. Benzinga

Nov 9, 2021

05:31PM EST Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer Business Wire

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:08AM EST Merck Reports Pending Acquisition Of Acceleron Pharma Cleared By Competition Authorities In Germany, Austria Benzinga

Nov 5, 2021

09:22AM EDT Acceleron Pharma Q3 EPS $(1.16) Down From $(0.66) YoY, Sales $34.20M Up From $22.56M YoY Benzinga

Nov 4, 2021

04:01PM EDT Acceleron Reports Third Quarter 2021 Financial Results Business Wire

Nov 2, 2021

10:27AM EDT Merck Pushes Acceleron Buyout By Refiling For Antitrust Review Benzinga

Oct 28, 2021

08:00AM EDT Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders Business Wire

Oct 27, 2021

07:50AM EDT Acceleron Q3 REBLOZYL Net Sales $160M Benzinga

07:27AM EDT Acceleron Expects To Report Royalty Revenue Of $32.0 Mlnfrom Net Sales Of REBLOZYL In Q3 RTTNews

07:10AM EDT Acceleron Announces Third Quarter 2021 REBLOZYL(r) Net Sales Business Wire

Oct 21, 2021

01:11PM EDT Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg Benzinga

12:11PM EDT Bloomberg Reported Late Wednesday Bristol-myers Squibb Plans to Tender Its Shares in Acceleron Pharma Following Merck Agreement to Acquire the Biotech Company Benzinga

Oct 20, 2021

08:07AM EDT Acceleron Pharma Shareholder Darwin Global Urges Co. Shareholders Not To Tender Shares To Merck Benzinga

Oct 13, 2021

03:32PM EDT Holocene Advisors Says Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company Benzinga

Oct 12, 2021

06:48AM EDT Merck Begins Tender Offer To Acquire Acceleron Pharma Inc. Benzinga

Oct 7, 2021

12:20PM EDT Expert Ratings For Acceleron Pharma Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

05:01AM EDT Jefferies Initiates Coverage On Acceleron Pharma with Hold Rating, Announces Price Target of $180 Benzinga

Oct 5, 2021

12:34PM EDT Acceleron Pharma 13D Filing From Avoro Capital Shows 7.3% Stake In Co. Benzinga

Oct 4, 2021

02:12PM EDT Where Acceleron Pharma Stands With Analysts Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021 Benzinga

07:16AM EDT Raymond James Downgrades Acceleron Pharma to Market Perform Benzinga

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Oct 1, 2021

06:27PM EDT ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRN Business Wire

12:49PM EDT Expert Ratings For Acceleron Pharma Benzinga

12:40PM EDT Morgan Stanley Downgrades Acceleron Pharma to Equal-Weight, Announces $180 Price Target Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021 Benzinga

07:30AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:12AM EDT Barclays Downgrades Acceleron Pharma to Equal-Weight, Raises Price Target to $180 Benzinga

05:31AM EDT Cowen & Co. Downgrades Acceleron Pharma to Market Perform, Raises Price Target to $180 Benzinga

Sep 30, 2021

03:54PM EDT Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma Benzinga

11:50AM EDT HC Wainwright & Co. Downgrades Acceleron Pharma to Neutral, Raises Price Target to $180 Benzinga

11:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 Benzinga

09:29AM EDT Piper Sandler Downgrades Acceleron Pharma to Neutral, Raises Price Target to $180 Benzinga

08:35AM EDT SVB Leerink Maintains Market Perform on Acceleron Pharma, Raises Price Target to $180 Benzinga

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

06:48AM EDT Merck To Acquire Acceleron Pharma For $180/Share In Cash For An Approximate Total Equity Value Of $11.5B Benzinga

Sep 29, 2021

12:19PM EDT Acceleron Pharma Option Alert: Nov 19 $190 Calls at the Ask: 12250 @ $6.0 vs 13 OI; Earnings 11/4 After Close [est] Ref=$182.65 Benzinga

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

08:54AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 28, 2021: XLRN, TSLA, DBGI, ANY, CEI Benzinga

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

06:03AM EDT A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data, Fed Speakers Benzinga

Sep 27, 2021

05:37PM EDT Merck Near A Deal To Buy Acceleron Pharma Benzinga

10:02AM EDT Shares of Acceleron Pharma Inc. (XLRN) are gaining over 5% on Monday morning on reports that an unnamed buyer is considering to buy the company for $11 billion. RTTNews

07:53AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:32AM EDT RBC Capital Maintains Sector Perform on Acceleron Pharma, Raises Price Target to $179 Benzinga

05:53AM EDT Acceleron In Advanced $11B Buyout Talks: Bloomberg Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Aug 5, 2021

05:37PM EDT Acceleron Pharma: Q2 Earnings Insights Benzinga

04:35PM EDT Acceleron Pharma Q2 EPS $(1.05) Misses $(0.88) Estimate, Sales $27.94M Miss $33.44M Estimate Benzinga

04:01PM EDT Acceleron Reports Second Quarter 2021 Financial Results Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 28, 2021

07:15AM EDT Acceleron Sees Q2 REBLOZYL Net Sales ~128M, Royalty Sales Of ~$25.6M Benzinga

07:10AM EDT Acceleron Announces Second Quarter 2021 REBLOZYL(r) Net Sales Business Wire

Jul 26, 2021

07:00AM EDT Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021 Business Wire

Jun 11, 2021

05:43AM EDT Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) announced Friday the first data from the Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent or NTD beta thalassemia. RTTNews

05:04AM EDT Bristol Myers Squibb And Acceleron Pharma Present First Data From Phase 2 BEYOND Study On Reblozyl RTTNews

Jun 8, 2021

07:00AM EDT Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021 Business Wire

May 19, 2021

03:16PM EDT Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients Benzinga

08:26AM EDT Acceleron Presents Interim Results From Open-label Extension Of PULSAR Phase 2 Trial Of Sotatercept At ATS 2021 RTTNews

08:20AM EDT Acceleron Pharma Presents Preliminary Interim Data From SPECTRA Phase 2 Trial Of Sotatercept RTTNews

08:01AM EDT Acceleron Highlights Presentation Of Prelim. Data From SPECTRA Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension At American Thoracic Society 2021 International Conference Benzinga

08:00AM EDT Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference Business Wire

08:00AM EDT Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference Business Wire

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 12, 2021

11:02AM EDT Acceleron Announces Presentations On REBLOZYL At 2021 European Hematology Association Virtual Congress RTTNews

10:57AM EDT Acceleron Announces Presentations on REBLOZYL(r) (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress Business Wire

May 11, 2021

07:02AM EDT Acceleron To Host Conference Call And Webcast To Review Clinical Trial Updates, Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension Presented At The American Thoracic Society 2021 International Conference Benzinga

07:00AM EDT Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International Conference Business Wire

May 6, 2021

04:23PM EDT Acceleron Pharma Q1 EPS $(1.05) Misses $(0.81) Estimate, Sales $24.76M Miss $28.89M Estimate Benzinga

04:01PM EDT Acceleron Reports First Quarter 2021 Financial Results Business Wire

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

10:06AM EDT Acceleron Pharma's Earnings: A Preview Benzinga

Apr 29, 2021

07:35AM EDT Acceleron Pharma Q4 EPS $(0.95) Misses $(0.59) Estimate, Sales $25.87M Miss $32.31M Estimate Benzinga

07:10AM EDT Acceleron Announces First Quarter 2021 REBLOZYL(r) Net Sales Business Wire

Apr 28, 2021

11:16AM EDT Acceleron Pharma Shares Move Lower; Traders Circulate FDA Filing Of Notice Of Noncompliance With Requirements For Submission Of Clinical Trail Results Benzinga

Apr 26, 2021

07:00AM EDT Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021 Business Wire

Apr 5, 2021

07:14AM EDT Acceleron Announces Clinical Trial Updates, Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension RTTNews

07:01AM EDT Acceleron To Present At American Thoracic Society 2021 International Conference May 19 Benzinga

07:00AM EDT Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference Business Wire

Apr 1, 2021

07:01AM EDT New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension Benzinga

Mar 23, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021 Benzinga

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

07:14AM EDT SVB Leerink Downgrades Acceleron Pharma to Market Perform, Announces $148 Price Target Benzinga

Mar 22, 2021

07:40AM EDT Goldman Sachs Assumes Acceleron Pharma at Neutral, Announces Price Target of $132 Benzinga

Mar 12, 2021

09:02AM EST Wolfe Research Initiates Coverage On Acceleron Pharma with Outperform Rating, Announces Price Target of $200 Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Mar 1, 2021

11:23AM EST Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $171 Benzinga

Feb 26, 2021

11:17AM EST Piper Sandler Maintains Overweight on Acceleron Pharma, Raises Price Target to $143 Benzinga

09:13AM EST Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $145 Benzinga

07:52AM EST 10 Biggest Price Target Changes For Friday Benzinga

07:18AM EST SVB Leerink Maintains Outperform on Acceleron Pharma, Raises Price Target to $148 Benzinga

Feb 25, 2021

05:00PM EST Recap: Acceleron Pharma Q4 Earnings Benzinga

04:25PM EST Acceleron Pharma Q4 EPS $(0.95) Misses $(0.59) Estimate, Sales $25.87M Miss $32.31M Estimate Benzinga

04:01PM EST Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

07:00AM EST Acceleron to Participate in Two Upcoming Healthcare Investor Conferences Business Wire

Feb 17, 2021

07:00AM EST Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 Business Wire

Feb 16, 2021

12:13PM EST Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia Benzinga

07:39AM EST Health Canada Approves REBLOZYL, New Class Of Treatment For Adult Patients Living With Myelodysplastic Syndromes Benzinga

07:37AM EST Health Canada Approves REBLOZYL(r) (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes Business Wire

Feb 4, 2021

07:57AM EST Acceleron Pharma Expects About $23.0 Mln In Royalty Revenue For Q4 RTTNews

07:27AM EST Acceleron Expects To Report ~$23M In Royalty Revenue For Q4 From Net Sales Of REBLOZYL, Expects $54.8M In Royalty Revenue For FY20 Benzinga

07:10AM EST Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL(r) Net Sales Business Wire

Jan 29, 2021

11:41AM EST JP Morgan Maintains Overweight on Acceleron Pharma, Raises Price Target to $153 Benzinga

Jan 19, 2021

08:28AM EST Raymond James Maintains Strong Buy on Acceleron Pharma, Raises Price Target to $160 Benzinga

06:24AM EST HC Wainwright & Co. Maintains Buy on Acceleron Pharma, Raises Price Target to $168 Benzinga

Jan 4, 2021

07:00AM EST Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 Business Wire

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 16, 2020

12:01PM EST Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $135 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

07:17AM EST Acceleron Gets Orphan Designation From European Commission For Sotatercept In Pulmonary Arterial Hypertension RTTNews

07:13AM EST Acceleron Receives Orphan Designation from the European Commission for Sotatercept in Pulmonary Arterial Hypertension Benzinga

07:00AM EST Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH) Business Wire

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 1, 2020

07:09AM EST Acceleron Receives FDA Orphan Drug Designation For ACE-1334 For Treatment Of Systemic Sclerosis RTTNews

07:00AM EST Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis Business Wire

Nov 25, 2020

10:27AM EST Acceleron Granted FDA Orphan Drug Designation For ' Treatment of systemic sclerosis' Benzinga

Nov 16, 2020

08:59AM EST Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to $131 Benzinga

Nov 13, 2020

10:02AM EST Acceleron Presents New Data From PULSAR Phase 2 Trial, Preclinical Research On Sotatercept In Pulmonary Arterial Hypertension At The 2020 American Heart Association Scientific Sessions Benzinga

10:01AM EST Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions Business Wire

10:00AM EST Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions Business Wire

Nov 9, 2020

07:00AM EST Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions Business Wire

Nov 6, 2020

11:02AM EST Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $130 Benzinga

10:34AM EST SVB Leerink Maintains Outperform on Acceleron Pharma, Raises Price Target to $138 Benzinga

06:30AM EST HC Wainwright & Co. Maintains Buy on Acceleron Pharma, Raises Price Target to $148 Benzinga

Nov 5, 2020

04:08PM EST Acceleron Pharma Q3 EPS $(0.66) Misses $(0.61) Estimate, Sales $22.56M Miss $26.27M Estimate Benzinga

04:01PM EST Acceleron Reports Third Quarter 2020 Operating and Financial Results Business Wire

07:57AM EST Acceleron Expects Royalty Revenue Of About $19.3 Mln From Net Sales Of REBLOZYL In Q3 RTTNews

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:30AM EST Acceleron Pharma Sees Prelim. Q3 Royalty Revenues ~$19.3M From ~$96M In Net Sales Of Reblozyl Benzinga

07:15AM EST Acceleron Announces Third Quarter 2020 REBLOZYL(r) Net Sales Business Wire

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

04:01PM EST Acceleron Announces REBLOZYL(r) (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

07:00AM EDT Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020 Business Wire

Oct 13, 2020

08:08AM EDT Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $125 Benzinga

Sep 29, 2020

08:26AM EDT Bristol Myers Squibb Canada or BMS and Acceleron Pharma Inc. (XLRN) said Tuesday that Health Canada has approved Reblozyl (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta-thalassemia. RTTNews

07:05AM EDT Bristol Myers Squibb Canada And Acceleron Pharma Announce Health Canada Approves REBLOZYL RTTNews

07:03AM EDT Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living with Beta-Thalassemia Benzinga

06:59AM EDT Health Canada Approves REBLOZYL(r) (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia Business Wire

Sep 17, 2020

04:01PM EDT Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020 Business Wire

Sep 16, 2020

07:04AM EDT Acceleron Pharma Appoints Laura Hamill To Its Board RTTNews

07:00AM EDT Acceleron Appoints Laura J. Hamill to its Board of Directors Business Wire

Aug 7, 2020

10:13AM EDT Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to $135 Benzinga

08:59AM EDT SVB Leerink Maintains Outperform on Acceleron Pharma, Raises Price Target to $134 Benzinga

Aug 6, 2020

04:12PM EDT Acceleron Pharma Q2 EPS $(0.34) Beats $(0.57) Estimate, Sales $39.75M Beat $30.08M Estimate Benzinga

04:01PM EDT Acceleron Reports Second Quarter 2020 Operating and Financial Results Business Wire

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:12AM EDT Acceleron Sees Q2 REBLOZYL Royalty Sales $11.1M Benzinga

07:10AM EDT Acceleron Announces Second Quarter 2020 REBLOZYL(r) Net Sales Business Wire

Jul 27, 2020

07:00AM EDT Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020 Business Wire

Jul 15, 2020

09:20AM EDT Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $123 Benzinga

Jul 11, 2020

05:42PM EDT Notable Insider Buys: Acceleron, Continental And Syneos Health Benzinga

Share